One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1093/annonc/mdz242.027
Copy DOI
Export
Save
Share
Cite Journal: Annals of Oncology |  Publication Date: Oct 1, 2019 |
 License type: publisher-specific-oa |
Affiliation: Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Institut de Cancérologie de l'Ouest, Centre Léon Bérard, Institute of Cancer Research of Montpellier, Azienda Ospedaliera Sant'Andrea, National Institute of Emergency Medicine "Pirogov", Spaarne Ziekenhuis, Institut Jules Bordet, Novartis (United States), KU Leuven
332P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
